

Cancer

A Study of Atezolizumab in Advanced Solid Tumors

Trial Status
Completed

Trial Runs In
18 Countries

Trial Identifier
NCT02458638 2015-000269-30
MO29518

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02458638 2015-000269-30 MO29518
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years

Healthy Volunteers
No
